Business Context and Reporting Period
Company: NanoViricides, Inc. (NNVC)
Filing Type: Form 8-K (Current Report)
Report Date: July 24, 2026
Event: Entry into a Material Definitive Agreement for a registered direct offering.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than periodic operating results. Key transaction metrics include:
- Gross Proceeds: Approximately $3.8 million.
- Securities Issued:
- 2,416,339 shares of Common Stock at $1.53 per share.
- 100,000 Pre-Funded Warrants at $1.52999 per warrant.
- Common Warrants to purchase up to 2,516,339 shares.
- Warrant Terms: Common Warrants have an exercise price of $1.75 per share, exercisable six months post-issuance, expiring 5.5 years from issuance.
- Placement Fees: 7.0% cash fee of gross proceeds plus up to $50,000 in reimbursable expenses.
Material Changes and Use of Proceeds
The primary material change is the increase in equity capital and potential dilution from the issuance of new shares and warrants. The filing does not provide comparative financial data (revenue, profit, or cash flow) for prior periods.
Intended Use of Proceeds: Working capital, capital expenditures, research and development, clinical trial expenditures, acquisitions, and other strategic purposes.
Outlook, Risks, and Contingencies
- Lock-Up Agreement: The CEO and principal stockholder (TheraCour Pharma, Inc.) are restricted from selling or transferring shares for 30 days following the closing date (July 27, 2026).
- Issuance Restriction: The Company agreed not to issue or announce the issuance of additional Common Stock or equivalents for 60 days post-closing, with limited exceptions.
- Registration Obligations: The Company must file a resale registration statement within 30 days of closing and bear associated expenses.
Investor Verification Checklist
- Verify the final net proceeds after deducting the 7% placement fee and offering expenses.
- Confirm the effective date of the Resale Registration Statement for the warrants.
- Monitor the 30-day lock-up expiration for the CEO and TheraCour Pharma, Inc. for potential selling pressure.
- Review the specific clinical trial milestones or R&D projects funded by the $3.8 million in subsequent disclosures.